Purpose: To evaluate treatment options for vitreomacular traction (VMT). Methods: A retrospective, consecutive case series and a literature search with Boolean search logic. A random-effects meta-analysis was conducted to combine the rates of VMT resolution per treatment. Patients from studies analyzed were placed into cohorts based on the treatment received.
P
osterior vitreous detachment (PVD) is a common condition in which the external vitreous face separates from the retina, usually as a result of the vitreous body losing its gel-like consistency and becoming more liquefied with age, myopia, trauma, or in association with hereditary syndromes. 1 The process should resolve spontaneously with complete separation of the posterior vitreous from the retina. However, if there are abnormally strong vitreomacular adhesions (VMA) between the vitreous and the retina, contraction of the vitreous results in vitreomacular traction (VMT) and distortion of the neurosensory retina. 1 VMT (which by definition must be associated with a VMA) distorts the normal foveal architecture and retinal vessels, typically resulting in cystoid macular edema, retinoschesis, macular breaks, photoreceptor disruption, and/or retinal pigment epithelial (RPE) disturbances associated with or without vitelliform material. These retinal and retinal pigment epithelial changes may result in decreased visual acuity or distortion of vision and thus be termed symptomatic. [2] [3] [4] Whether these visual changes are permanent or reversible with successful lysis of the VMA depends on the severity and chronicity of VMT and the ultimate ultrastructural changes in the retina and RPE.
Until recently, the only treatment options for VMT were observation and pars plana vitrectomy (PPV). Observation remains the least invasive treatment option for VMT, and although spontaneous VMT resolution is generally understood to occur infrequently, there are published case series arguing for its efficacy. [5] [6] [7] Some reports suggest a potential role for watchful waiting before PPV, 5 but others suggest it may only prove useful for certain patients with less advanced stages of VMT. [8] [9] [10] Given the inconsistent efficacy of observation and the risks associated with PPV, including infection, retinal tears and detachment, and increased risk of glaucoma and cataract formation, other less invasive but effective treatment options have been developed. 11 Pharmacological vitreolysis through the recently approved ocriplasmin (Jetrea; Thrombogenics Inc, USA, Alcon/Novartis EU) has shown some promise as a possibly less invasive alternative to surgery for patients with VMT. Ocriplasmin is a recombinant truncated version of human plasmin that digests laminin, fibronectin, and Type 4 collagen; induces liquefaction of the vitreous; and helps release and dissolve vitreous attachments from the retina. In the Microplasmin for Intravitreous Injection-Traction Release without Surgical Treatment (MIVI-TRUST) trials, a single intravitreal injection of ocriplasmin (IVO) significantly improved the rate of VMA resolution when compared with a saline placebo injection (n = 652, P , 0.001). 12 However, IVO also resulted in several complications, including retinal tears and detachment, 12 temporary ellipsoid zone attenuation, [13] [14] [15] [16] transient subretinal fluid, 17 retinal breaks, 18, 19 reduced visual acuity 20 , and vitreous floaters. 20 A case report from Fahim et al 14 documented visual field constriction and attenuation of the external limiting membrane and photoreceptor ellipsoid layer because of IVO, suggesting that IVO-related retinal complications may extend beyond the macular region. Tibbetts et al 15 reported a similar finding of ellipsoid layer attenuation, which resulted in darkened vision. Also, Thanos et al 16 reported distinct changes after IVO injection in the ellipsoid zone of photoreceptors associated with reduced visual acuity, which gradually recovered over a 3-month follow-up period. These reported complications indicate that there is still much to be learned about the specific effects of ocriplasmin. Nation-wide studies, like the second collaborative Macula Society Project: Ocriplasmin Outcomes Study, will foster understanding of ocriplasmin use in the clinical setting. This ongoing study is currently collecting data, like VMT resolution rate and complications, from physicians with experience in treating VMT patients with IVO.
A less frequently reported treatment option, pneumatic vitreolysis (PV), is an intravitreal injection of an expansile gas bubble that can be used to massage the tractional vitreomacular interface thereby yielding VMT release. In 1995, Chan et al, published a clinical study using PV to treat full-thickness macular holes (FTMH) associated with VMT. This study reported a high rate of resolution with 10 of 11 (90.9%) Stage I FTMH. . .and FTMH closure of 3 of 6 (50%) patients with Stage II FTMH. 21 Studies since then have looked exclusively at VMT patients with 22 or without 23 FTMH, but all have confirmed similar efficaciousness with mention of only a few serious complications.
Although not a widely published treatment option, PV has shown promising results in an extensive range of VMT severity levels. Such interest has sparked clinical trial initiation: The RELEASE clinical trial, measuring the efficacy of an intravitreal injection of sulfahexafluoride gas (SF 6 ) for VMA resolution without a concurrent macular hole, is currently recruiting patients. Given these initial reports, we began in January 2014 to offer PV to our patients at the Beth Israel Deaconess Medical Center (BIDMC) with VMT. The present clinical series attempts to compare all available treatment options for VMT (except watchful waiting) in patients with similar ocular findings treated by the same physician surgeon at the same institution. We also performed a meta-analysis of the published literature to assess the rate of VMT resolution among patients who received 1 of 3 options: a control injection of saline, IVO, or PV. Complications due to IVO, PV, and PPV were also compiled. The results of our case series were included in the meta-analysis that is presented in this article.
Methods
This retrospective study analyzed a consecutive series of patients diagnosed with VMT, as verified by Spectral Domain Optical Coherence Tomography (SD-OCT), who elected to undergo one of the following treatment options between May 2011 and June 2014: PV with octafluoropropane (C 3 F 8 ), IVO, or PPV with membrane peeling. Institutional Review Board (IRB)/ Ethics Committee approval was obtained for this study, and it adhered to the tenets of the Declaration of Helsinki. Because this study was completed retrospectively, a HIPAA Waiver of Consent was obtained from the Institutional Review Board, and no informed consent forms were needed. VMA and VMT were defined as a broad (.1,500 mm) or focal adhesion (#1,500 mm) at the macula that did not (for VMA) or did (for VMT) result in distortion of the neurosensory retina on SD-OCT. Because all patients that had VMA were symptomatic, they were characterized as VMT, as referenced by Stalmans et al. 2 All 25 horizontal and vertical cross-sectional scans obtained through SD-OCT were reviewed for each patient in the study to confirm adhesion and presence or absence of a full-thickness macular hole before treatment. We identified "control patients" as those who had VMT with concurrent neovascular age-related macular degeneration and were treated with only an anti-VEGF agent, similar to Almeida et al. 9 A single physician surgeon at the BIDMC administered all treatments. Thirty patients were included in this study (n = 35 eyes). All patients underwent comprehensive ocular evaluation before treatment, including discussion of previous eye-related symptoms and history, Snellen visual acuity, tonometry, and SD-OCT. Patients who had an epiretinal membrane, proliferative diabetic retinopathy, or clinically significant macular edema in the treated eye were included in this study, and patients were included regardless of FTMH status before treatment.
Procedures
Control patients had a concurrent diagnosis of neovascular age-related macular degeneration, nonproliferative diabetic retinopathy, central retinal vein occlusion, and/or branch retinal vein occlusion (Table 1) findings on SD-OCT of VMA or VMT. They received only 1 anti-VEGF injection (bevacizumab, ranibizumab, or aflibercept) before the main outcome measure of VMT resolution by Day 28. The treatment was completed using sterile injection techniques in-office and per the specified package insert guidelines for the selected anti-VEGF treatment. The patients were first given topical anesthetic proparacaine and/or lidocaine gel with or without a subconjunctival lidocaine injection, a wire lid speculum was placed, and 5% and 10% betadine was administered as a disinfectant. Intravitreal injection was performed superotemporally using a 30-gauge needle 4 mm posterior to the limbus. Visual acuities in these patients were not evaluated because comparison against the other cohorts with entirely different treatment conditions would have been biased.
Patients undergoing an intravitreal injection of the expansile gas C 3 F 8 were treated in-office. After the same pretreatment procedure, 0.3 mL of 100% perfluropropane (C 3 F 8 ) gas from Alcon ISPAN was injected intravitreally through the pars plana using a 30-gauge needle and a 1-mL syringe. A paracentesis was also performed to decrease intraocular pressure. After the procedure, patients were instructed to remain facedown 15 minutes every hour while awake for 48 hours after treatment.
Patients who elected for ocriplasmin treatment received a single intravitreal injection of 125 mg of ocriplasmin using the same pretreatment procedure. The treatment was administered using sterile injection techniques within the FDA-approved package insert guidelines for ocriplasmin.
Patients treated by PPV received a posterior sub-Tenon's infusion of 0.75% Marcaine and 2% Lidocaine using a 19-gauge irrigating cannula before surgery. A 23-gauge PPV was performed with epiretinal membrane peeling if present and internal limiting membrane peeling with indocyanine green (ICG) dye staining. If a macular hole was identified preoperatively or intraoperatively, then the patient was left with 25% SF 6 gas tamponade and advised to maintain a face-down position 45 minutes every hour while awake for 7 days.
Outcome Measurements
To improve our ability to compare our case series with other studies in the literature, we used outcome measures that were as similar as possible to those used in the MIVI-TRUST trials. 12 The MIVI-TRUST trials were two multicenter, double-blind Phase 3 trials evaluating the efficacy of a single intravitreal injection of ocriplasmin for the treatment of symptomatic VMA versus a placebo injection of saline. The primary endpoint of the trial was VMA resolution by Day 28 and the secondary endpoints were complete PVD by Day 28, nonsurgical FTMH closure by Day 28, and improved visual acuity by at least three lines using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart by 6 months.
The primary endpoint of the presented case series was the incidence of VMT resolution by Day 28 as defined by no visible vitreous adherence to the fovea on SD-OCT. Secondary endpoints included the nonsurgical incidence of FTMH closure at any follow-up time and complication rate.
Literature Review
A literature review was undertaken using PubMed MEDLINE as the sole database for article acquisition. Articles from May 1988 to January 2015 were found using Boolean operators with the following search terms: PPV, PV, gas, perfluoropropane, C 3 F 8 , sulfahexafluoride gas, sulfur hexafluoride, ocriplasmin, pharmacologic vitreolysis, VMT, VMA, vitreofoveal traction, taut posterior hyaloid, and vitreous detachment. The PPV studies were only included to determine the complication rates of all available treatment options.
Only English articles with primary data using human subjects from peer-reviewed journals were included in this meta-analysis, and reviews and articles
with tertiary documentation of data were excluded. Articles that did not explicitly provide numbers for the rate of VMT resolution among their cohorts and articles that did not explicitly study VMT were also excluded from this study. For example, McHugh et al 24 documented the incidence of posterior vitreous detachment for a cohort of patients using intravitreal gas injection to treat proliferative diabetic retinopathy, not VMT. Thus, this article was not included in this analysis. To be included in this study, the article also needed to clearly define what type of treatment was administered and describe the technique enough for it to be clearly identified as PV or IVO. Finally, to avoid potential publishing bias, only studies that specifically stated patient cases were selected consecutively were included in this analysis. For example, the study conducted by Odrobina et al 25 that looked at spontaneous VMT resolution in observation patients was included in this analysis; although technically considered a retrospective study, the authors outlined the case-selection method for choosing patients by retrospectively and consecutively searching the OCT images of 10,239 patients and excluding patients with initial vascular diseases, retinal tears and detachments, and other underlying criteria.
The primary outcome measure of this meta-analysis was VMT resolution at 28 days. VMT resolution was defined as "VMT resolution," "VMA resolution," or "complete PVD" as explicitly stated in the articles included in this analysis. "Partial release" was not considered a valid outcome in our analysis. For example, Knudson et al described some patients as undergoing a "partial resolution," but only the patients with complete resolution were included in the rate of VMT resolution. 26 The rate of FTMH closure at any followup period was also analyzed from articles that reported this information. Any adverse events listed in the articles were tabulated with particular emphasis on endophthalmitis, retinal breaks and tears, MH development, and retinal detachment (RD). To determine the rate of adverse events for each treatment type, the total number of patients per treatment type was calculated as the sum of the study numbers in articles that explicitly stated that their patients developed no complications or listed one of the four emphasized complications as an adverse event, suggesting that the particular adverse events in question was analyzed and recorded among the patients studied.
A funnel plot was created and heterogeneity statistic using each study's VMT resolution proportions and variances was calculated to assess the variability among studies using Stata software (version: IC 12, 62-bit, Windows). Owing to a statistically significant heterogeneity statistic, a random-effects model was used to weight the rates of VMT resolution and MH closure in the combined analysis with a MantelHaenszel transformation applied for rates that had an outcome of 0.
Statistical Analysis
Several statistical tests were completed for each specific outcome measure, and unless specified otherwise, all tests were performed in Statistical Analysis System statistics software (version 9.3, SAS; SAS Institute, Cary, NC). The significance level for all statistical tests was set to P , 0.05. To determine statistically significant differences in the demographic information, an analysis of variance test (ANOVA) was conducted. Equal variances were not assumed. For the clinical case series, the incidence of VMT resolution for PPV, IVO, and PV was compared against the control cohort respectively for statistically significant differences. No factors were found to be significant factors when compared against VMT resolution rates (diabetic status, the presence of FTMH, epiretinal membrane status, sex, age, eye; Table 2 ), so a univariate test was completed. For the meta-analysis, many studies did not include this level of detail for their patient cohorts. Owing to lack of available data and thus potentially biased results, a statistical analysis was not performed on the rates found by meta-analysis.
Results

BIDMC Clinical Case Series
For the clinical case series, 35 eyes from 30 patients with VMT as observed by SD-OCT were treated with placebo (n = 10 eyes), PV (n = 8 eyes), IVO (n = 7 eyes), and PPV (n = 10 eyes). The mean ages at treatment were 67.1 (range: 57-92), 68.6 (range: 52-76), 66.3 (range: 55-79), and 68.5 years (range: 40-93) for placebo, PV, IVO, and PPV, respectively, and a total of 14 men and 16 women were treated. There were no statistically significant differences in the ages, ratio of men to women treated, and ratio of right eye to left eye treated among the treatment cohorts. Pre-and posttreatment demographic information is presented in Table 1 .
By Day 28, the primary outcome measurement of VMT resolution was achieved in 0 of 10 control patients (0%), 7 of 8 patients treated with PV (87.5%), 3 of 7 patients treated with IVO (42.9%), and 10 of 10 patients who underwent PPV (100%). Both PV (P = 0.0005) and PPV (P , 0.0001) had significantly higher rates of VMT resolution compared with the agematched controls, but IVO did not (P = 0.10). The frequency of VMT resolution was higher for PV patients compared to that of patients receiving IVO, however this trend was not significant (87.5% vs. 43.9%; P = 0.20). Similarly, there was no significant difference in VMT resolution for PV versus PPV (P = 0.89). The amount of adhesion was measured for each patient, and all patients had focal adhesions (focal ,1,500 mm). The largest adhesion was 1,324 mm and the smallest was 80 mm. PV resulted in no MH closure after treatment (n = 1 eye, 0%), and IVO resulted in MH closure for 1 of 3 eyes (33.3%).
Of those that failed to respond to treatment, two patients treated with IVO later underwent PPV to treat the persistent VMT and MH, as well as one patient treated with PV. Complications that resulted from PV included MH development (n = 1 eye). For IVO, one patient had increased subretinal fluid and an irregular photoreceptor layer. For PPV, two patients experienced atrophic photoreceptor changes posttreatment. None of the patients treated with PV or IVO experienced a worsening of their vision by at least 3 lines at Month 6, but 2 of 9 patients treated with PPV (22.2%) experienced worsened vision by 3 lines.
Literature Review
For the literature review excluding our case series, 131 articles were identified using the aforementioned Boolean search techniques. Ninety-six articles were initially excluded because they were one of the following: reviews (n = 55, 1 was a meta-analysis), articles that did not study human eyes (n = 15), articles that did not specifically test natural VMA or VMT patients (n = 11; 2 articles analyzed VMT because of trauma, 3 analyzed RD and excluded VMT patients, and 8 studied various other diseases without specifying whether all cases had VMT), articles not written in English (n = 10), or articles that studied an initial form of ocriplasmin not FDA approved (n = 5). Of the remaining 35 articles, 12 more articles were excluded because they were case reports (n = 8) or nonconsecutive, retrospective reviews (n = 4), so that 23 articles were analyzed, 15 for weighted VMT resolution and 8 for analysis of complications post-PPV treatment. 12, 13, 17, [19] [20] [21] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] A total of 1,007 eyes diagnosed with VMA or VMT from 15 eligible studies were included in the meta-analysis, not including the BIDMC case series, and 142 eyes treated with PPV were included to understand complications rates (Table 3) . For the literature review including our case series, a total of 1,042 eyes were studied: the same 253 control patients to avoid variability, 726 IVO, and 63 PV. Previous dx of CME AMD, age-related macular degeneration; Appts, appointments; CF, count fingers; CME, cystoid macular edema; CSME, clinically significant macular edema; Dx, diagnosis; F, female;
IVO, intravitreal ocriplasmin; M, male; Mac Tel, macular telangiectasia; N, no; N/A, not applicable (for VA at 6 months, N/A represents patients who did not have a 6 month follow-up before completion of this study); NPDR, non-proliferative diabetic retinopathy; NT, not taken; PED, pigment epithelial detachment; PR, photoreceptor; SRF, sub-retinal fluid; Sx, surgery;
Tx, treatment; Y, yes. Table 4 .
None of the studies, including the BIDMC series, reported cases of endophthalmitis. FTMH formation was associated with all treatment options a FTMH developed in 2 of 49 PV-treated cases (4.1%), 29 of 756 IVO-treated cases (3.8%), and 7 of 241 PPV cases (2.9%). There were no reported cases of RDs or retinal breaks or tears in patients treated with PV. In contrast, IVO had the highest rate of retinal breaks or tears (22 of 756, 2.9%), followed by PPV (5 of 241, 2.1%). IVO also had 5 of 756 cases of RDs (0.7%), and PPV had 4 of 241 (1.7%). A summary of complications by treatment type is presented in Table 5 .
Discussion
This was a two-part study, evaluating the efficacy of an intravitreal gas injection with face-down positioning for the treatment of VMT against other available treatment options within (1) a single treatment facility and (2) a literature review of published cases. No previous case series comparing all treatment options available to VMT patients within the same clinic was found. Neither was a previous meta-analysis of all available treatment options. Our case series confirmed that PPV has the highest efficacy in treating VMT, as compared with the other nonsurgical options. When all patients are combined regardless of FTMH status before treatment, both the case series and the metaanalysis showed that PV had a higher rate of VMT resolution compared with IVO at Day 28.
The 87.5% success rate for VMT resolution with PV at Day 28 in this case series was lower than previously published case series, like Chan et al, who observed a total of 6 Stage 2 eyes and 11 VMT-only eyes with a 94% success rate of VMT resolution, and Mori et al, who observed 20 FTMH patients with a 95% success rate. 21, 22 But our success rate was higher than Rodrigues et al, 23 the most recently published study using intravitreal injections of C 3 F 8 , who observed a 40% success rate in 15 eyes without a FTMH but with diabetic macular edema (n = 6 eyes). Conversely, our rate of VMT resolution with IVO (42.9%) was higher than previous reported studies (e.g., 26 .5% success in MIVI-TRUST 12 ). Our case study combined with a relatively large number of patients treated with PV (n = 63) and IVO (n = 764) in the literature provides evidence that PV is not only a viable treatment option for VMT, but may also yield greater efficacy than IVO in patients with VMT.
The secondary outcome measure of MH closure also showed consistently higher rates of success in PV-treated patients compared with IVO-treated patients within the case series and the meta-analysis. Rodrigues et al 23 postulated that IVO might show lower rates of VMT resolution because the injection of the plasmin protease only pharmacologically loosens the VMA without providing a tractional force necessary to take advantage of the diminished adhesion. Additionally, the proposed mechanism by which vitrectomy with intraocular gas tamponade results in FTMH closure has been well documented and could provide an explanation for why PV results in a higher The following variables were not significant against the rates of VMT resolution and treatment type, and thus a multivariate regression was not performed: diabetic status (P = 0.21), FTMH presence (P = 0.45), ERM status (P = 0.42), sex (P = 0.62), age (P = 0.67), and eye (P = 0.64).
*Presented P values in the table were calculated against the control injection rates.
VITREOMACULAR TRACTION TREATMENT YU ET AL 7 FTMH closure rate than placebo and IVO. Specifically, PV induces both VMT resolution through creation of a tractional force and provides internal tamponade that may lead to FTMH closure. 42 It is possible that using a combination of IVO and PV may increase rate of VMT resolution even further, although additional studies would be required.
FTMH status is an important characteristic to consider when choosing available treatment options for VMT release. It has been recommended that ocriplasmin should be reserved for patients who screen for positive baseline predictors of successful VMT release, including lack of a FTMH before treatment, but other studies argue that the absence of these factors does not mean treatment should be avoided. 20, 27 The results of the presented study might indicate that PV may be more efficacious in more advanced cases of VMT outside the positive baseline predictors, but further studies are needed to confirm these initial findings.
Although the ranking of treatments for the main outcome measure of VMT resolution at Day 28 was concordant between the case series and the literature review, the secondary outcome measures differed. In the BIDMC case series, IVO had a higher frequency of MH closure than PV (33.3% for IVO; 0% for PV), but in the literature analysis, PV had a higher rate of MH closure compared with IVO (PV: 0.59 [95% CI: 0.12-1], IVO: 0.36 [95% CI: 0.11-0.60]). The large confidence intervals indicate the high variability and uncertainty in the data because of the lack of published data available to analyze; thus, these results should be considered with this awareness. However, the consistency in the main outcome measures the consistency in the main outcome measures indicate the robustness of VMT resolution at Day 28, even with small sample sizes.
Outside PV and IVO, observation has also shown efficacy in VMT resolution in past studies, although longer follow-up times were generally required. John et al 6 recently published a case series of VMT patients managed initially with observation, 34 patients achieving spontaneous VMT resolution (32.1%) over a mean follow-up of 18 months. John et al.'s 6 average followup time was toward the median; the average follow-up times for observation ranged from 8 months to 5 years. [5] [6] [7] [8] [9] [10] 25, 40 John et al 6 also found VMT resolution is generally higher in patients with asymptomatic or noncritical VMT. Dimopoulos et al 5 found 20 of 46 patients (43.7%) had spontaneous VMT resolution at a median follow-up of 594 days, and concluded a shorter follow-up time might have underestimated the rate of spontaneous resolution in clinical trials like MIVI-TRUST. These studies indicate observation might provide a good option for asymptomatic or mildly symptomatic VMA patients.
The lack of retinal tears and RDs associated with PV found in the meta-analysis was surprising and may be due to the fact that none of the patients, by definition, had a complete PVD prior to treatment. This is in contrast to patients with an acute PVD and RD treated with pneumatic retinopexy who have an approximate 30% risk of a "new" retinal break after the procedure. 43 We believe that the vitreous state (no PVD or PVD) and timing of PVD (acute vs. chronic) before intravitreal gas injection are important factors related to the risk of new retinal tear formation.
We certainly realize that there are limitations in a case series and meta-analysis. For example, our case series had a limited number of patients. Also, given the relatively few articles evaluating PV efficacy and the still novel aspect of using this treatment over the other available options, the articles published on PV-treated patients might not provide an accurate representation of VMT resolution in a clinical setting because of publication bias. The funnel plot obtained also suggested this finding (see Figure Supplemental Digital Content 1, http://links.lww.com/IAE/A418). A large prospective case series or randomized clinical trial of PV versus ocriplasmin is needed to fully delineate the efficacy and complications of these nonsurgical procedures. Owing to these limitations, these results suggest that PV may be as effective or superior to only non surgical treatment options for VMT.
Despite these limitations, that our consecutive case series and meta-analysis of the literature provide useful information that confirms the positive results previously published on VMT treatment with PV, suggesting that it may provide a safe, cost-effective, minimally invasive alternative to current treatment options for VMT. In our meta-analysis, PV resulted in a higher rate of VMT release compared with IVO at Day 28 and had a similar risk profile as PPV and IVO without any reported cases of retinal breaks, tears, or detachments. PV also resulted in a higher rate of MH closure. PV should be studied further in a prospective fashion to better delineate the benefits and risks associated with this promising procedure.
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